MERCK AND MODERNA ANNOUNCE PHASE 3 INTERPATH-001 TRIAL OF INTISMERAN AUTOGENE PLUS KEYTRUDA® MET ENDPOINTS OF RECURRENCE-FREE SURVIVAL (RFS) AND DISTANT METASTASIS-FREE SURVIVAL (DMFS) IN PATIENTS WITH COMPLETELY RESECTED STAGE IIB-IV MELANOMA

Reuters · 2d ago

Please log in to view news